Category: Coloplast

  • PharmaShots Weekly Snapshots (November 08 – 12, 2021)

    Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer’s Disease at CTAD 2021 Published: Nov 12, 2021 | Tags: Eisai, Lecanemab, P-IIb, Study 201 Study, Alzheimer’s Disease, CTAD 2021 Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity Published: Nov 12, 2021 | Tags: Novo Nordisk, […]

  • Coloplast to Acquire Atos Medical for ~$2.49B

    Shots: Coloplast to acquire Atos Medical for an enterprise value of $2.49B from PAI Partners. The transaction is expected to close in Q2’22 Coloplast obtains access to a new chronic care segment to be run as a separate strategic business unit operating on shared Coloplast infrastructure that also supports its offerings in urology, continence and […]

  • PharmaShots Weekly Snapshot (Nov 02-06, 2020)

    AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Approval to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Published: Nov 6, 2020 | Tags: AstraZeneca, Brilinta, ticagrelor, Receives, US FDA, Approval, Acute, High,Risk, Transient, Ischaemic, Stroke Novo Nordisk to Acquire Emisphere Technologies for $1.8B Published: Nov 6, […]

  • Coloplast Acquires Nine Continents Medical

    Shots: Coloplast has acquired implantable tibial nerve stimulation (ITNS) treatment developer Nine Continents Medical for $145M upfront and an additional contingent milestone. ITNS is developed for overactive bladder (OAB) Coloplast expected to initiate clinical studies of ITNS in 2021 with the goal to obtain pre-market approval for a Class III device in the US and […]